Two key questions can be raised about platelet transfusions (PTXs) for neonates (defined for this editorial as preterm infants during the first month following delivery). First, do sound evidence-based guidelines exist to decide when PTX should be given? The short answer is "no". Second, when a PTX is prescribed, do we know how to select and transfuse the best available platelet product? Fortunately for this question, the answer is "yes". The longer, more detailed answers to these two questions are outlined in the remainder of this article.
Guidelines for neonatal PTXs
It is generally accepted that human neonates have blood platelet counts within the same normal range as older children and adults (i.e., 150,000-450,000/µl). However, recent data suggest a lower normal limit of 120,000/µl for preterm neonates during the first days following birth [1] . Using the conventional lower limit of 150,000/ µl for normal values, below 1% of term neonates experience thrombo cytopenia [2] ; whereas 20-35% of preterm neonates admitted to a neonatal intensive-care unit (NICU) will have blood platelet counts less than 150,000/µl [3, 4] . When only a subset of extremely low birthweight neonates (<1000 g at delivery) were considered, 73% had one or more platelet counts below 150,000/µl [3] . Among all thrombocytopenic preterm neonates, 25-38% will have blood platelet counts less than 50,000/µl (i.e., severe thrombocyto penia) and will probably receive PTXs [3] [4] [5] . Thus, between 2 and 8% of all preterm neonates admitted to an NICU will receive a PTX [5] , with extremely low birthweight neonates given PTX much more frequently (45% in one report [3] ).
Since only one randomized controlled trial studying PTXs in preterm neonates has been reported [6] , the practice of neonatal PTXs is based almost entirely on 'level 4 evidence' (i.e., expert opinion and reasoning), and practices vary widely [5] . Andrew et al.'s randomized clinical trial enrolled preterm neonates during the first week of life and assigned them to either a group in which PTXs were given liberally to keep the blood platelet count within the normal range (i.e., to receive a PTX whenever the blood platelet count fell below 150,000/µl), or a group that received a PTX for specific reasons related to true thrombocytopenia (i.e., clinical concern about bleeding or whenever the blood platelet count fell below 50,000/ µl) [6] . Neonates who were thrombocytopenic before possible enrollment were excluded. Since neonates in the first group received a PTX whenever their blood platelet count fell below the 150,000/ µl lower limit of the normal range, their average daily platelet counts were above 200,000/µl. Neonates in the second group were transfused at a mean platelet count of 60,000/µl and their average daily platelet counts were also relatively high at more than 100,000/µl. There was no difµl. There was no dif-. There was no difference between groups in the incidence of intracranial hemorrhage (28 vs 26%), the primary end point of the trial. Thus, there was no benefit in maintaining the blood platelet count within the normal "It is widely agreed that the blood platelet count should not fall below 50,000/µl in preterm neonates who exhibit active bleeding or are at a great risk of bleeding…"
It is widely agreed that the blood platelet count should not fall below 50,000/µl in preterm neonates who exhibit active bleeding or are at a great risk of bleeding (e.g., when a surgical or invasive procedure, such as a lumbar puncture, is to be performed) [4, 5] . For these neonates, many physicians elect to give PTXs whenever the platelet count falls below 100,000/µl and expand the definition of 'great risk of bleeding' to include neonates receiving indomethacin, neonates with grade II intraventricular hemorrhage, neonates with sepsis and neonates with necrotizing enterocolitis -decisions not supported by definitive or even highly suggestive data/information from properly designed and conducted clinical trials [5] . Importantly, the vast majority (>90% in one study [3] ) of PTXs are administered prophylactically to neonates who have no evidence of bleeding. Approximately 50% of neonatologists selected a relatively high blood platelet count of 50,000/µl as the 'transfusion trigger', for extremely low-birthweight neonates [5] despite the absence of apparent bleeding -again, a practice not supported by definitive data/information.
Transfusing the best platelet product
When a PTX is prescribed for a thrombocytopenic neonate, the usual goal is to increase the blood platelet count by 50,000-100,000/µl above the pretransfusion count (e.g., from a 40,000/µl pretransfusion platelet count to a post-transfusion platelet count between 90,000 and 140,000/µl). As has been reported [6] -and is consistent with my own experience -this increment can be achieved by transfusing 10 ml/kg (infant body weight) of an unmodified platelet unit (either a platelet concentrate prepared from a whole-blood unit or a platelet unit prepared by an apheresis platelet collection). Routinely reducing the volume of platelet concentrates and increasing the number of platelets per milliliter for infants, by means of additional centrifugation steps, is both unnecessary and unwise -unless it is specifically required.
Transfusion of 10-ml/kg platelet concentrate, taken directly from the unit and transfused, provides approximately 10 × 10 9 platelets. If the blood volume of an infant is 70 ml/kg bodyweight and the plasma volume is 40 ml/kg, the platelet dose of 10 ml/kg can be calculated to increase the platelet count by 100 × 10 9 to 150 × 10 9 /l above the pretransfusion baseline -assuming a post-transfusion platelet recovery of 60%. This calculated increment is consistent with the actual increment reported in human infants administered PTX [6] . With modest thrombocytopenia, a smaller 5-ml/kg dose may be sufficient to raise the post-transfusion platelet count to above 100,000/µl. In general, 5-10 ml/kg is not an excessive transfusion volume for sick neonates, as long as the intake of other intravenous fluids, medications and nutrients is adjusted. Thus, there appears no logical reason to routinely volume-reduce/concentrate platelet units before transfusion to infants.
In the selection of platelet units for transfusion, it is desirable that the infant and the platelet donor be of the same ABO blood group. It is important to minimize repeated transfusions of group O platelets to group A or B recipients, because large quantities of passive anti-A or anti-B in the plasma can lead to hemolysis. This should be easily avoided, except in the directed-donor situation, in which the infant may be forced to receive platelet transfusions from an out-of-group donor (i.e., not of the identical ABO group). Hopefully, sound medical sense will prevail in these situations, and ABO-identical platelets from the general bloodbank inventory will be selected, rather than taking the risks of directed donation.
"In the selection of platelet units for transfusion, it
is desirable that the infant and the platelet donor be of the same ABO blood group."
Proven methods exist to reduce the volume of platelet concentrates but should only be employed when it is truly warranted (e.g., multiple transfusions anticipated from directed donors in which several doses of passive anti-A or anti-B may lead to hemolysis, or documented failure to respond to a transfusion of 10-ml/kg unmodified platelet concentrate). If volume reduction must be carried out, additional processing should be performed with great care. The method of reduction and the efficacy of platelet transfusions after reduction must be validated locally to ensure the quantity and quality of platelets (both ex vivo and in vivo) remains after modification.
Conclusion
Many preterm neonates, particularly those with birthweight below 1000 g, exhibit thrombocytopenia and receive PTX. Most PTXs are administered prophylactically to nonbleeding neonates in the belief that they are at risk of developing serious bleeding. Risks of PTXs include transmission of infectious organisms, such as bacteria, infusion of cytokines and other potential toxins, such as plasticizers, and transfusion reactions -including those caused by donor antibodies to red blood cell antigens and transfusion-related acute lung injury. Moreover, the mortality rate of neonates given PTX is double that of nontransfused neonates -although mortality can not be directly ascribed to PTX per se.
Accordingly, until more-definitive data are available, it seems prudent to transfuse 10 ml/kg (infant body weight) of an unmodified platelet concentrate to preterm neonates when any one of the following occurs: active bleeding or definite threat of bleeding posed by an invasive procedure/surgery and fall in Editorial Platelet transfusions in neonates: questions & answers the blood platelet count to below 100,000/µl; potential threat of increased bleeding posed by the development of grade 2 intracranial hemorrhage, indomethacin therapy, sepsis or necrotizing enterocolitis and a fall of the blood platelet count to below 50,000/µl; when blood PTL count falls below 30,000/µl in clinically stable neonates with no apparent increased bleeding risks (prophylaxis).
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